Dataset Information

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST).

ABSTRACT: BACKGROUND:Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel symptom diary for bronchiectasis symptom burden and detection of exacerbations, named the BEST diary. METHODS:Prospective observational study of patients with bronchiectasis conducted at Ninewells Hospital, Dundee. We included patients with confirmed bronchiectasis by computed tomography, who were symptomatic and had at least 1 documented exacerbation of bronchiectasis in the previous 12?months to participate. Symptoms were recorded daily in a diary incorporating cough, sputum volume, sputum colour, dyspnoea, fatigue and systemic disturbance scored from 0 to 26. RESULTS:Twenty-one patients were included in the study. We identified 29 reported (treated exacerbations) and 23 unreported (untreated) exacerbations over 6-month follow-up. The BEST diary score showed a good correlation with the established and validated questionnaires and measures of health status (COPD Assessment Test, r =?0.61, p =?0.0037, Leicester Cough Questionnaire, r =?-?0.52,p =?0.0015, St Georges Respiratory Questionnaire, r =?0.61,p

SUBMITTER: Artaraz A

PROVIDER: S-EPMC6958700 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST).

Artaraz Amaia A Crichton Megan L ML Finch Simon S Abo-Leyah Hani H Goeminne Pieter P Aliberti Stefano S Fardon Thomas T Chalmers James D JD

Respiratory research 20200113 1

<h4>Background</h4>Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel symptom diary for bronchiectasis symptom burden ...[more]

PMID: 31931782

Similar Datasets

Project description:BackgroundZheng represents pattern differentiation in Traditional Chinese Medicine (TCM), as the basic unit and a key concept in TCM therapeutic theory, is based on the physiology and pathology of TCM. None of the outcome measurements of atopic dermatitis (AD) are Zheng-specific. The effectiveness of TCM is likely to be underestimated without a Zheng-related symptom-specific instrument. The aim of this study was to develop an instrument for measuring the Zheng-related symptom-specific status of patients with AD.MethodsWe followed standard methodology to develop the instrument, including item generation and selection, item reduction and presentation, and pretesting, and recruited 188 patients with AD involved in a six-center randomized-controlled trial (ChiCTR-TRC-08000156) to validate the questionnaire. We conducted construct validity, reliability, and responsiveness analysis. The standardized effect size (SES) and standardized response mean (SRM) were used to calculate the responsiveness of additional items and the total score for the rating items.ResultsZRADSQ has 15 items, with 12 rating items and 3 additional items. The 12 rating items fall within three domains: AD symptoms (n = 6 items); Heat (n = 4 items) and Mood (n = 2 items). Confirmatory factor analysis provided good support for a three-factor model (d.f. = 51, x2=97.11, RMSEA = 0.07, CFI = 0.96), and the Pearson's correlation coefficient between ZRADSQ and Severity Scoring of Atopic Dermatitis (SCORAD) was 0.40 (P < 0.001). The reliability was also good, with a Cronbach's alpha value for ZRADSQ of 0.84, a split-half coefficient of 0.75, and a test-retest reliability coefficient of 0.98. The standardized effect size and standardized response mean were close to or larger than 1, which indicated moderate to good responsiveness.ConclusionsThe ZRADSQ demonstrates promising reliability, validity, and responsiveness. It can be used to determine whether Zheng-specific or symptom-specific treatments relieve the symptom that is most bothersome the patient.

Project description:BackgroundBest Practice Alerts (BPAs) are alert messages to physicians in the electronic health record that are used to encourage appropriate use of health care resources. While these alerts are helpful in both improving care and reducing costs, BPAs are often broadly applied nonselectively across entire patient populations. The development of large language models (LLMs) provides an opportunity to selectively identify patients for BPAs.ObjectiveIn this paper, we present an example case where an LLM screening tool is used to select patients appropriate for a BPA encouraging the prescription of deep vein thrombosis (DVT) anticoagulation prophylaxis. The artificial intelligence (AI) screening tool was developed to identify patients experiencing acute bleeding and exclude them from receiving a DVT prophylaxis BPA.MethodsOur AI screening tool used a BioMed-RoBERTa (Robustly Optimized Bidirectional Encoder Representations from Transformers Pretraining Approach; AllenAI) model to perform classification of physician notes, identifying patients without active bleeding and thus appropriate for a thromboembolism prophylaxis BPA. The BioMed-RoBERTa model was fine-tuned using 500 history and physical notes of patients from the MIMIC-III (Medical Information Mart for Intensive Care) database who were not prescribed anticoagulation. A development set of 300 MIMIC patient notes was used to determine the model's hyperparameters, and a separate test set of 300 patient notes was used to evaluate the screening tool.ResultsOur MIMIC-III test set population of 300 patients included 72 patients with bleeding (ie, were not appropriate for a DVT prophylaxis BPA) and 228 without bleeding who were appropriate for a DVT prophylaxis BPA. The AI screening tool achieved impressive accuracy with a precision-recall area under the curve of 0.82 (95% CI 0.75-0.89) and a receiver operator curve area under the curve of 0.89 (95% CI 0.84-0.94). The screening tool reduced the number of patients who would trigger an alert by 20% (240 instead of 300 alerts) and increased alert applicability by 14.8% (218 [90.8%] positive alerts from 240 total alerts instead of 228 [76%] positive alerts from 300 total alerts), compared to nonselectively sending alerts for all patients.ConclusionsThese results show a proof of concept on how language models can be used as a screening tool for BPAs. We provide an example AI screening tool that uses a HIPAA (Health Insurance Portability and Accountability Act)-compliant BioMed-RoBERTa model deployed with minimal computing power. Larger models (eg, Generative Pre-trained Transformers-3, Generative Pre-trained Transformers-4, and Pathways Language Model) will exhibit superior performance but require data use agreements to be HIPAA compliant. We anticipate LLMs to revolutionize quality improvement in hospital medicine.

Project description:ImportanceBreslow thickness is a 1-dimensional surrogate prognostic feature for tumor size, yet tissue sections have 2 dimensions. Therefore, a 2-dimensional feature, calculated tumor area (CTA), was devised.ObjectiveTo determine CTA precision and prognostic value.Design, setting, and participantsThis retrospective cohort of patients with cutaneous melanoma presented to the Leicester and Nottingham National Health Service hospital trusts in the United Kingdom. Eligible patients in the Leicester development sample had available primary tumor tissue; a diagnosis from January 1, 2004, through December 31, 2011; invasive disease; and Leicestershire residency. Patients in the Nottingham validation sample had an anonymized spreadsheet with primary melanoma diagnosed from January 1, 2003, through December 31, 2005, or from January 1, 2008, through December 31, 2010. From a starting population of 1463 patients in both data sets, a total of 224 (15.3%) were excluded to yield a study population of 1239. Data were analyzed from April 30, 2018, through January 10, 2019.InterventionAn observational analysis of the prognostic value of CTA in patients with cutaneous melanoma.Main outcomes and measuresIndependent association of CTA with melanoma-specific survival and confounding effect of CTA on Breslow thickness in survival analysis.ResultsA total of 1239 patients with melanoma were assessed, including 649 (52.4%) women, with a median age of 60 years (interquartile range, 47-71 years). An intraclass correlation coefficient for CTA on 13 cases was 0.99. In 918 patients in the Leicester cohort, CTA was an independent prognostic factor in Cox proportional hazards regression models after adjusting for Breslow thickness, age, sex, ulcer, mitotic rate, and microsatellites (hazard ratio [HR], 1.87; 95% CI, 1.49-2.34; P < .001). Validation in 321 patients in the Nottingham cohort showed an HR of 1.55 (95% CI, 1.15-2.09; P = .005) and in the combined 1239 cases, an HR of 1.70 (95% CI, 1.43-2.03; P < .001). Breslow thickness was significant in multivariable analysis only when CTA was not in the model. The relative importance of CTA was shown by its retention in all 100 bootstrap multivariable models with backward selection, whereas Breslow thickness was retained in only 53. Melanomas stratified by CTA showed wider separation of survival curves than those stratified by Breslow thickness using the American Joint Committee on Cancer Staging Manual, 8th Edition (HRs, 1.00 to 41.46 vs 1.00 to 36.95, respectively), and the model with CTA categories had a Bayesian information criterion difference of 13.9 compared with T category, indicating substantially better fit. This model had a Harrell C index of 83.7%, and bootstrap analysis showed little evidence of model optimism, with a corrected calibration slope of 0.99.Conclusions and relevanceThis study provides a novel microscopic feature, CTA, with evidence of its independent prognostic value. This evidence suggests that CTA should be a priority for further study.

Dataset Information

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST).

Publications

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets